Side effects Both share a glucagon-driven profile, which means both can modestly raise resting heart rate, something their cardiovascular trials are evaluating
The delivery method (telehealth versus in-person) doesn't change the safety of the medication or the prescribing standards
Retatrutide is an investigational triple hormone receptor agonist that simultaneously targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Once absorbed from the subcutaneous tissue, semaglutide binds to GLP-1 receptors in multiple tissues, including pancreatic beta cells, where it enhances glucose-dependent insulin secretion
Until recently, oral glutathione was thought to be ineffective at raising intracellular levels of glutathione, due to the molecules being lost during digestion